Product category:
Reagents and catalysts
News Release from: Nanogen | Subject: MGB Alert
Edited by the Laboratorytalk Editorial
Team on 28 July 2006
Nanogen releases new real-time PCR
reagents
MGB Alert real-time PCR reagents assist laboratories in developing tests that can detect sequences associated with varicella-zoster virus (VZV, also called Human Herpesvirus 3) and Bordetella bacteria
Vaccines exist for both VZV and Bordetella, but the conditions they cause remain endemic for several reasons VZV infection causes chicken pox, and its reactivation can trigger the painful neurological disorder shingles
This article was originally published on Laboratorytalk on 27 Apr 2006 at 8.00am (UK)
Related stories
Detection of Epstein-Barr virus (EBV)
EBV, Epstein-Barr virus, is the causative agent of infectious mononucleosis and also underlies several other lymphoproliferative disorders such as Burkitt's lymphoma
$2.5M to develop diagnostics for sepsis, pneumonia
Grant will enable Nanogen to develop improved molecular biological methods, miniaturise those methods, and demonstrate this new molecular diagnostic approach in a hospital laboratory setting
Varicella is an opportunistic pathogen in immuno-compromised individuals and causes severe reactions in children with leukemia and lymphoma.
In these cases, rapid diagnosis is needed in order to begin a course of appropriate antiviral therapy.
In addition, the proportion of atypical VZV cases has risen, increasing the need for laboratory confirmation of physicians' diagnoses.
Further reading
Fluorescent detection of nucleic acid targets
Patent relates to latent fluorophore-minor groove binder oligonucleotide conjugates which fluoresce upon hybridisation to a target
Molecular biology on second-generation chip system
Open and robust platform allows laboratories to use one system for multiple molecular applications, including the detection of SNPs and multi-gene targets for pharmacogenetics
Bordetella pertussis and Bordetella parapertussis are the causative organisms for pertussis infection (whooping cough) in humans.
Because the current vaccine for Bordetella is only approved for children under seven and does not convey life-long protection, whooping cough has persisted in teens and adults.
The vaccine is also not completely effective; breakthrough disease occurs in vaccinated individuals.
"Reagents that can be used in the laboratory-developed tests to detect VZV and Bordetella are the latest addition to Nanogen's MGB Alert real-time PCR analyte specific reagents (ASRs)," said Howard Birndorf, Nanogen chairman and CEO.
"Diagnosis by real-time PCR is possible within a few hours, as compared to traditional culture methods that can take days." PCR tests are also regarded as more accurate and sensitive than currently available direct immunofluorescent assays (DFAs).
All MGB Alert products utilise patented detection chemistry that enables laboratories to develop multiple assays with universal parameters, increasing the efficiency and throughput of clinical testing.
The super bases (Super A, Super T, Super G and Super N) and MGB technology allow the use of shorter probes with increased sensitivity to mismatches, which have proved essential for detecting short conserved sequences.
Nanogen's advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease.
The company's products include real-time PCR reagents, the NanoChip electronic microarray platform and a line of rapid, point-of-care diagnostic tests.
Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturisation and continues to be supported for its potential for diagnostic and biodefense applications.
• Nanogen: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
